PON1, paraoxonase 1, 5444

N. diseases: 496; N. variants: 29
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE Groups were evaluated at baseline for presence of MS, blood markers of metabolism, homeostasis model assessment of insulin resistance (HOMA-IR) score, and biochemical markers of inflammation (hs-CRP, IL-1β, IL-6, TNF-α and PON-1). 31134465 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE Utility of sICAM-1 and PON1 as surrogate prognostic biomarkers and putative therapeutic targets in the management of diabetes and MetS is strongly suggested. 30327716 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE PON1 has been associated with diseases caused by high oxidative stress, whereas BuChE appears to be involved in the pathophysiology of the metabolic syndrome and related disorders. 29393817 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 AlteredExpression disease BEFREE The inverse relationship of PON-1 activity with free T<sub>4</sub> was not different in subjects with vs without MetS (P = .94), nor modified by the presence of its individual components (P ≥ .22 for each). 29171874 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE The apolipoprotein A5 Q139X, lipoprotein lipase (LPL) Hinf I, human paraoxonase 1 (PON1) 192Arg/Gln, cholesteryl ester transfer protein (CETP) Taq1B, adiponectin 45T>G and leptin (LEP) 25CAG were genotyped by real-time polymerase chain reaction in participants with and without MetS. 30381540 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 AlteredExpression disease BEFREE Shared pathways in both MetS and mood disorders are low grade inflammation, including increased levels of pro-inflammatory cytokines and acute phase proteins, increased lipid peroxidation with formation of malondialdehyde and oxidized low density lipoprotein cholesterol (LDL-c), hypernitrosylation, lowered levels of antioxidants, most importantly zinc and paraoxonase (PON1), increased bacterial translocation (leaky gut), increased atherogenic index of plasma and Castelli risk indices; and reduced levels of high-density lipoprotein (HDL-c) cholesterol. 28438472 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE PON1 activities were influenced by all three polymorphisms, regardless of the presence of MS. 26193203 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE According to our results, PON1 Q192R polymorphism is a risk marker for insulin resistance, a pathological factor involved in the development of metabolic syndrome. 25500007 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE There were no significant associations between PON1 Q192R genotypes and smoking by genotype interactions and obesity or overweight, while body mass index significantly increased MetS risk. 25037113 2014
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. 24028901 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease CTD_human Our results, in this first study, provide evidence for association of PON1 gene polymorphisms with the risk for metabolic syndrome. 21573798 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE Our results, in this first study, provide evidence for association of PON1 gene polymorphisms with the risk for metabolic syndrome. 21573798 2012
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE We studied oxidized LDL (OxLDL), OxLDL/LDL, OxLDL/HDL, lipoperoxides, autoantibodies against OxLDL (OxLDL-Ab), diene formation of LDL (lag phase), vitamin E, vitamin E/cholesterol and PON1 polymorphisms (-108C>T, 55T>A, and 192A>G) in 166 non-smoking type 2 diabetic patients, 119 fulfilling the criteria for the metabolic syndrome, 73 with atherosclerosis and 93 without atherosclerosis. 17904830 2008
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE We used adenovirus-mediated PON1 gene transfer (AdPON1) to overexpress human PON1 in mice with combined leptin and LDL receptor deficiency, a model of metabolic syndrome. 16627808 2006
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE Two hundred and twenty-four subjects met the diagnostic criteria of MS. We found a significant interaction between MS and both the PON1 polymorphisms in determining the risk of coronary artery disease (P<0.05 by likelihood-ratio test). 15928879 2005
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 AlteredExpression disease BEFREE Serum PON1 activity levels were found to be significantly lower, and lipid peroxide concentrations significantly higher, in subjects with the metabolic syndrome compared with unaffected subjects (P = 0.033 and < 0.001, respectively). 14602783 2003